紫杉醇治疗非小细胞肺癌研究的知识图谱演进、热点及趋势分析OA

Using bibliometric methods,this study systematically reviews the current state of research,evolving trends and future directions in the field of paclitaxel treatment for non-small cell lung cancer(NSCLC).Relevant Chinese and English literature from China National Knowledge Infrastructure(CNKI)and the Web of Science(WOS)Core Collection up to May 2026 was retrieved.CiteSpace 6.3.R1,VOSviewer 1.6.20.0 and Excel were utilised to conduct visual analyses of annual publication volume,research institutions,author collaboration,country distribution,keyword co-occurrence,clustering and emergence.The findings revealed that both Chinese and English literature exhibited a'germination-growth-plateau-decline'pattern,with the total volume of English literature significantly exceeding that of Chinese.International research has formed a high-intensity collaborative network centred on the United States.Research hotspots revolve around paclitaxel combined with platinum-based chemotherapy;English-language research places greater emphasis on cutting-edge topics such as randomised controlled trials,survival outcomes,targeted therapy,immunotherapy and nanomedicine,whilst Chinese-language research primarily focuses on efficacy,safety and localised clinical evaluation.Emergent terms indicate that international cutting-edge research has shifted from the comparison of chemotherapy regimens to combination therapy with immune checkpoint inhibitors.The field of paclitaxel treatment for NSCLC is transitioning from the optimisation of traditional chemotherapy towards a new phase characterised by the concurrent advancement of precision medicine,integrated approaches and translational research.Future efforts should strengthen biomarker screening,the elucidation of resistance mechanisms,and the integration of real-world evidence with high-quality clinical trials.